[go: up one dir, main page]

CN115667219A - 一种(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯二酸盐的制备方法 - Google Patents

一种(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯二酸盐的制备方法 Download PDF

Info

Publication number
CN115667219A
CN115667219A CN202180038387.8A CN202180038387A CN115667219A CN 115667219 A CN115667219 A CN 115667219A CN 202180038387 A CN202180038387 A CN 202180038387A CN 115667219 A CN115667219 A CN 115667219A
Authority
CN
China
Prior art keywords
phenyl
dimethylpyridine
amino
preparation
methyl propionate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180038387.8A
Other languages
English (en)
Other versions
CN115667219B (zh
Inventor
胡海文
胡范
周玉宝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Original Assignee
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd filed Critical Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Publication of CN115667219A publication Critical patent/CN115667219A/zh
Application granted granted Critical
Publication of CN115667219B publication Critical patent/CN115667219B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明提供了一种(S)‑2‑(3S,8S)‑3‑(4‑(3,4‑二氯苄氧基)苯基‑7‑((S)‑1‑苯丙基)‑2,3,6,7,8,9‑六氢‑[1,4]‑二氧杂环己烯并[2,3‑g]异喹啉‑8‑甲酰氨基)‑3‑(4‑(2,3‑二甲基吡啶‑4‑基)苯基)丙酸二盐酸盐的关键中间体(S)‑2‑氨基‑3‑[4‑(2,3‑二甲基吡啶‑4‑基)苯基]丙酸甲基酯二酸盐的制备方法，该方法与现有技术相比，无需经过色谱柱分离纯化，具有成本低、收率高的优点，更适合于工业化生产。

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN202180038387.8A 2020-05-28 2021-05-26 一种(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯二酸盐的制备方法 Active CN115667219B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010481657X 2020-05-28
CN202010481657 2020-05-28
PCT/CN2021/095965 WO2021238963A1 (zh) 2020-05-28 2021-05-26 一种(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯二酸盐的制备方法

Publications (2)

Publication Number Publication Date
CN115667219A true CN115667219A (zh) 2023-01-31
CN115667219B CN115667219B (zh) 2024-11-15

Family

ID=78745588

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180038387.8A Active CN115667219B (zh) 2020-05-28 2021-05-26 一种(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯二酸盐的制备方法

Country Status (5)

Country Link
US (1) US20230348483A1 (zh)
EP (1) EP4159719A4 (zh)
CN (1) CN115667219B (zh)
TW (1) TW202210461A (zh)
WO (1) WO2021238963A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12234236B1 (en) 2023-09-14 2025-02-25 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117500789A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法
CN115057845B (zh) * 2022-06-14 2024-05-03 山东罗欣药业集团恒欣药业有限公司 一种阿贝西利的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959405A (zh) * 2008-03-07 2011-01-26 转化技术制药公司 治疗糖尿病的氧杂二氮杂蒽化合物
CN102378574A (zh) * 2009-03-30 2012-03-14 转化技术制药公司 取代的偶氮蒽衍生物、药物组合物及其使用方法
CN105884752A (zh) * 2015-02-13 2016-08-24 山东轩竹医药科技有限公司 并环类回旋酶和拓扑异构酶iv抑制剂
CN106458994A (zh) * 2014-04-02 2017-02-22 百时美施贵宝公司 联芳激酶抑制剂
WO2019103060A1 (ja) * 2017-11-22 2019-05-31 第一三共株式会社 縮合三環化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959405A (zh) * 2008-03-07 2011-01-26 转化技术制药公司 治疗糖尿病的氧杂二氮杂蒽化合物
CN102378574A (zh) * 2009-03-30 2012-03-14 转化技术制药公司 取代的偶氮蒽衍生物、药物组合物及其使用方法
CN106458994A (zh) * 2014-04-02 2017-02-22 百时美施贵宝公司 联芳激酶抑制剂
CN105884752A (zh) * 2015-02-13 2016-08-24 山东轩竹医药科技有限公司 并环类回旋酶和拓扑异构酶iv抑制剂
WO2019103060A1 (ja) * 2017-11-22 2019-05-31 第一三共株式会社 縮合三環化合物
TW201925204A (zh) * 2017-11-22 2019-07-01 日商第一三共股份有限公司 稠合三環化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12234236B1 (en) 2023-09-14 2025-02-25 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof

Also Published As

Publication number Publication date
EP4159719A1 (en) 2023-04-05
US20230348483A1 (en) 2023-11-02
TW202210461A (zh) 2022-03-16
WO2021238963A1 (zh) 2021-12-02
EP4159719A4 (en) 2024-07-17
CN115667219B (zh) 2024-11-15

Similar Documents

Publication Publication Date Title
CN115667219A (zh) 一种(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯二酸盐的制备方法
de Vries et al. Organocatalytic asymmetric transfer hydrogenation of imines
Claraz et al. Asymmetric iodine catalysis-mediated enantioselective oxidative transformations
CN103003231A (zh) 制备苯基环丙基胺衍生物的新方法及其用于制备替卡格雷的用途
WO2020016749A3 (en) Chemical process for preparing phenylpiperidinyl indole derivatives
CN114650997A (zh) L-草铵膦的制备方法
Bao et al. An effective synthesis of bromoesters from aromatic aldehydes using tribromide ionic liquid based on L-prolinol as reagent and reaction medium under mild conditions
CN110461826A (zh) 依利格鲁司他的合成方法及其中间体化合物
Wang et al. Phosphine-Catalyzed (3+ 2) Annulation of δ-Acetoxy Allenoates with 2-Sulfonamidomalonate: Synthesis of Highly Substituted 3-Pyrrolines and Mechanistic Insight
Veverková et al. Squaramide-catalyzed Michael addition as a key step for the direct synthesis of GABAergic Drugs
Guo et al. Asymmetric transfer hydrogenation of 3-(trifluoromethyl) quinolines
US20180099919A1 (en) Process for the preparation of (1r,3r)- and (1s,3s)-2,2-dihalo-3-(substituted phenyl)cyclopropanecarboxylic acids
CN109790114A (zh) 新型手性配体、金属螯合物、多种非天然氨基酸、马拉维诺及其关键中间体的合成方法
WO2011090720A3 (en) Purification of proteins
US7683191B2 (en) Organic salts and method for producing chiral organic compounds
Trajkovic et al. Total synthesis of (+)-swainsonine and (+)-8-epi-swainsonine
CN104151171B (zh) 一种拆分制备光学纯r-1-萘乙胺的方法
JP6017451B2 (ja) 不斉触媒を用いる二環性化合物の光学分割方法
Wei et al. Straightforward access to densely substituted chiral succinimides through enantioselective organocatalyzed Michael addition of α-alkyl-cyclic ketones to maleimides
CN115768764A (zh) 一种具有抗肿瘤活性的并环类化合物及其用途
David et al. Ethyl dibromofluoroacetate: a versatile reagent for the synthesis of fluorinated molecules
CN114341155A (zh) 一种肽酰胺类化合物及其中间体的制备方法
RU2011114776A (ru) Этил 1,6-диарил-4-ароил-3-гидрокси-2-оксо-8-фенил-1,7-диазаспиро [4.4]нона-3,6,8-триен-9-карбоксилаты и способ их получения
JPH08151344A (ja) ２−（３−ベンゾイルフェニル）プロピオン酸の光学分割方法
JP2017095442A5 (zh)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant